West attended Newcastle University in the far north of England. Residents of Newcastle, called "Geordies," are famously enthusiastic soccer fans. He lived near St. James' Park, home of Newcastle United, and could hear the swelling roar of 52,000 fans whenever the team scored. West himself spent many hours playing as a goalkeeper. He also played in the university residence hall as a disk jockey, spinning anything from disco and Motown to hard rock late into the night.
Like a Fish to Water
West's priorities changed, however, in his senior year when he joined Peter Emmerson's biochemistry laboratory to complete a required undergraduate project. Emmerson was working to identify proteins that Escherichia coli produced after irradiation. Such proteins were likely involved in genetic repair, particularly through a process called homologous recombination.
Homologous recombination ensures the stability of genetic material. After DNA replication, each chromosome contains two copies of genetic material in two identical sister chromatids. When a double-strand DNA break occurs in one, the sister can serve as a template for repair. Mutations in the recombination system can impair the chromosome's ability to repair itself, potentially leading to cancer.
Working in Emmerson's cold room, West says he took to biochemistry "like a fish to water. I always knew the next experiment to do. I always knew how to approach a problem. I just loved it." With this newfound aptitude, West pursued a doctorate in Emmerson's laboratory. In the mid-1970s, biochemists trying to understand gene-repair processes were faced with the mystery of protein X (1), which was produced abundantly by cells in response to DNA damage, but whose cellular function was unknown. Concurrently, mutations in genes, including recA, were known to impair DNA repair by homologous recombination (2), but the protein product of recA was also unknown.
Amid international competition to identify protein X, West took advantage of a recently developed gelelectrophoresis technique (3) that would provide two dimensions of information: protein size on the vertical axis, and protein charge-or isoelectric point-on the horizontal axis. Using this technique, West saw that a mutation in E. coli, called tif1, led to the formation of a version of protein X that had a different charge from that found in wild-type cells. At about the same time, a research group in France mapped the tif1 mutation to the recA gene (4). West and Emmerson were one of three groups in 1977 to connect the dots showing that protein X was in fact the protein product of recA (5-7).
From Hessle to Yale
After earning his doctorate in 1977, West joined the laboratory of Paul Howard-Flanders at Yale University. Englishman Howard-Flanders was originally a physicist before becoming interested in the effects of radiation on bacteria, and had previously supervised Peter Emmerson's postdoctoral work. "This was a chance to work at one of the best universities in the world," West says. "How could a kid from Hessle ever end up at Yale? I loved every minute of it, from the first day." West expected Howard-Flanders to assign a research project, but after several weeks of conversations about politics, seminars, and sailing, West inferred that he was to set his own research course, and resumed working on protein X, now known as RecA.
"Of course, this was exactly what [HowardFlanders] wanted, but he wasn't going to tell me," West says. "This was the way he worked. He was a gentle, almost subliminal, influence."
After purifying RecA, West found that the protein formed rod-like filaments bound to DNA (8) . These nucleoprotein filaments were later shown to be the structures that initiated recombination (9). West then took two duplexes of DNA, one labeled with radioactive 32 P and the other with 3 H, and placed them in a test tube with RecA. After 30 minutes, he found that each duplex contained both radioactive labelsindicating DNA strand exchange-in reactions facilitated by a single protein, RecA (10) .
As before, West was not the only scientist working to piece together the RecA story, and was working contemporaneously with the laboratories of Charles Radding, also at Yale, and Robert Lehman of Stanford University. All three laboratories made rapid advances, and West completed his time at Yale with a strong portfolio of high-profile publications.
Holliday Junctions at Clare Hall
In 1985 West returned to England to join the new Clare Hall Laboratories in South Mimms, north of London. A year before, West had met Tomas Lindahl at a conference. Lindahl, who would later be awarded the Nobel Prize for Chemistry in 2015, told West that he was launching a new cancer research laboratory dedicated to DNA replication, recombination, and repair. Attracted by the prospect of designing his own laboratory and by the full support of the Imperial Cancer Research Fund, West joined Clare Hall to continue his work on recombination.
During his work on RecA at Yale, West had found that his in vitro recombination experiments contained reaction intermediates, called Holliday junctions (11) . Intrigued, West began looking for the enzymes in bacteria and yeast that would cut the Holliday junctions and drive the recombination process to completion. These enzymes are called Holliday junction resolvases. "It's clear that if RecA makes them," he says, "something has to get rid of them."
Now at Clare Hall, West and his laboratory found resolvase activity and partnered with geneticist Robert Lloyd to locate the genes that encoded the resolvase proteins. By 1990, they had the elements of the resolvase system worked out (12) . The researchers found that the E. coli resolvase was the product of the ruvC gene. In addition, they discovered that the proteins encoded by the closely related ruvA and ruvB genes guided the movement of Holliday junctions along DNA strands by a process known as branch migration (13) .
An 18-Year Search
West and his group then turned to identifying analogous resolvase proteins in human cells. The researchers observed resolvase activity in human cell extracts in 1990 (14), but would spend the next 18 years identifying the protein displaying that activity. "There was very little protein inside the cell," West says, "and since the protein was not physically related to RuvC in structure, it was very difficult to identify."
During those 18 years, however, other lines of research bore fruit. The laboratory purified RAD51, the human equivalent of RecA, as well as RAD52 and BRCA2, providing insight into the role of each protein in human recombination (15) (16) (17) . In another project, postdoctoral scholar Ivan Ahel discovered a role for Aprataxin, a protein defective in individuals with a debilitating neurodegenerative disease, in DNA repair (18). West had not assigned Ahel to work on Aprataxin, but Ahel was determined to study the protein. The hunt bore fruit in 2008, when postdoctoral scholar Stephen Ip purified enough of the human resolvase that recent advances in mass spectrometry technology could be used to identify the protein. After many years, the human Holliday junction resolvase finally had a name: GEN1. Concurrently, postdoctoral scholar Uli Rass set out to identify resolvases in yeast by independently expressing each gene and determining whether the product might be a resolvase. After screening around 2,000 genes, Rass identified the yeast Holliday junction resolvase as Yen1 protein, which was analogous to GEN1 (19) .
"In London we have a saying," West says, "that you wait for half an hour for a bus, and then two No. 8's come along at the same time. We had waited so long, and then somehow identified the equivalent yeast and human resolvases in the same month." West's Inaugural Article (20) describes the structure/sequence requirements for efficient Holliday junction resolution by GEN1. The discovery of GEN1 was only the beginning of the resolvase story. West and his team are now investigating the regulation and interplay of three distinct resolution pathways in human cells and how defects in these pathways can lead to cancer (21).
West's work in teasing apart the mechanisms of chromosome recombination and DNA repair is firmly in the realm of basic research, but it has a bearing on cancer, particularly in the role of the BRCA2 gene in breast and ovarian cancer. He recently showed how the BRCA2 gene product, BRCA2 protein, helps RAD51 initiate recombination (22) . Given that people with defective BRCA2 genes often develop breast or ovarian cancers, insights into recombination biochemistry might aid the fight against cancer.
"Our knowledge of the pathways of DNA repair is now at a level where it is possible to begin to design novel drugs that can control or eliminate tumor formation by specifically targeting our DNA repair pathways," he says. "In this regard, the future looks bright."
